Novartis’ Shaw Pushing For U.S. Outcomes-Based Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Country Head Christi Shaw talked in an interview about Novartis’ near-term growth drivers – namely the heart failure drug LCZ696 – and how Novartis is evaluating outcomes-based reimbursement models to address growing payer pressure in the U.S.